Atea Pharmaceuticals, Inc.
A Boston drug developer that makes oral antiviral medicines for serious viral infections, with its lead program pairing bemnifosbuvir and ruzasvir against hepatitis C. It was founded in 2012 by Jean-Pierre Sommadossi, a co-founder of Pharmasset, the company behind the hepatitis C treatment sofosbuvir, sold as Sovaldi. Sommadossi helped build that earlier drug, and Atea carries forward the same nucleoside antiviral science.
Granted 1.02M · Sold 115.9K
Granted 214.1K · Sold 15.8K
Granted 92.3K · Bought 25.0K · Sold 401.3K
Granted 117.5K · Sold 11.8K
Granted 92.3K
Granted 162.9K · Sold 14.0K
Granted 92.3K · Sold 17.5K
Granted 92.3K · Bought 18.1K
Granted 144.1K · Sold 15.9K
Granted 92.3K
Granted 92.3K
Granted 116.0K · Sold 12.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Sommadossi Jean-PierrePresident, CEO, and Chairman, Director · 12 transactions | — | 6.63M | 1.02M | — | 115.9K |
| Corcoran AndreaSee Remarks · 8 transactions | +30.1% | 823.6K | 214.1K | — | 15.8K |
| Berger Franklin MDirector · 8 transactions | -34.6% | 536.1K | 92.3K | 25.0K | 401.3K |
| Vavricka JohnChief Commercial Officer · 7 transactions | — | 176.7K | 117.5K | — | 11.8K |
| Lucidi BrunoDirector · 3 transactions | +184.7% | 142.3K | 92.3K | — | — |
| Hammond Janet MJChief Development Officer · 7 transactions | — | 127.7K | 162.9K | — | 14.0K |
| Polsky BruceDirector · 4 transactions | +149.6% | 124.8K | 92.3K | — | 17.5K |
| Murphy Polly A.Director · 5 transactions | — | 121.7K | 92.3K | 18.1K | — |
| Horga Maria ArantxaChief Medical Officer · 7 transactions | — | 112.2K | 144.1K | — | 15.9K |
| Adams Jerome M.Director · 3 transactions | — | 92.3K | 92.3K | — | — |
| Duncan Barbara GayleDirector · 3 transactions | — | 92.3K | 92.3K | — | — |
| Foster WayneEVP, Chief Accounting Officer · 7 transactions | — | 91.5K | 116.0K | — | 12.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -561.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.